Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, discusses the management of patients with non-small cell lung cancer (NSCLC) who also have high PDL1 expression. Dr Cappuzzo outlines the use of immunotherapies in combination with chemotherapy, highlighting poor outcomes with immunotherapy alone in patients with NSCLC and high PDL1 expression. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
- Management of patients with PDL1-high advanced NSCLC ( Download)
- Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic Landscape ( Download)
- Immunotherapeutics with Dr. James Gulley ( Download)
- The Leading Treatment Options for Advanced NSCLC and High PDL-1 - Mandarin Lung Cancer Video Library ( Download)
- How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC ( Download)
- Updates in the Management of Lung Cancer ( Download)
- How does PD-L1 impact treatment options for lung cancer ( Download)
- Lung Cancer Breakout: Breakthrough treatments for longer life ( Download)
- Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Download)
- Dr. Desai on Immunotherapy in Patients With NSCLC and Low PD-L1 Expression ( Download)
- Stanford Cancer Institute Breakthroughs in Cancer: Luis Diaz, MD ( Download)
- Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Front Line Therapy ( Download)
- PD-L1/PD-1 Cancer Immunotherapy and New Targets - Gordon Freeman, PhD ( Download)
- Are You Prepared for the New Wave of ADCs in NSCLC Targeting HER2, HER3, TROP2, and Others ( Download)
- Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC ( Download)
